Horii, T., Yoshimoto, M., Kobayashi, A., Kondo, C., Matsubara, N., Funasaka, C., Nakajima, H., Kuboki, Y., Ito, K., Murakami, M., Ito, S., Higuchi, T., Kanazawa, N., Funase, Y., Kano, D., Inagaki, A., Mochinaga, S., Inagawa, H., Kobayashi, T., Inaki, A. (2025). First-in-human phase 0 safety, imaging, pharmacokinetics, and dosimetry study of
            <sup>64</sup>
            Cu-PD-32766, a carbonic anhydrase IX (CAIX)-targeting peptide, in patients with clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.tps605